{
    "clinical_study": {
        "@rank": "121232", 
        "brief_summary": {
            "textblock": "To provide product through an expanded access program to HIV-infected patients with CD4\n      counts less than 300 cells/ml."
        }, 
        "brief_title": "An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV-1 seropositivity.\n\n          -  CD4 counts < 300 cells/ml.\n\n        NOTE:\n\n          -  If a patient's CD4 count is 275 to 300 cells/ml, the patient must either rescreen for\n             Study 806 or wait 6 months before entering the expanded access program.\n\n          -  Patient must have failed or been intolerant to other comparable or alternative\n             marketed therapies or must not be a candidate for such therapies.\n\n          -  Patient must not meet inclusion criteria for other Remune trials.\n\n          -  Patient must have laboratory tests within specified limits.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Clinically significant cardiac, hepatic, renal, or gastrointestinal dysfunction.\n\n          -  Current participation in a Remune study.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Use of any immune-modulating drugs.\n\n          -  Induction therapy or initiation of new treatment regimen for an AIDS-defining\n             condition.\n\n        Patients with any of the following prior conditions are excluded:\n\n        Previous participation in a Remune study.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Use of any immune-modulating drugs within 3 months of Day 1 visit.\n\n          -  Induction therapy or initiation of new treatment regimen for an AIDS-defining\n             condition within 30 days of Day 1 visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002172", 
            "org_study_id": "093", 
            "secondary_id": "901"
        }, 
        "intervention": {
            "intervention_name": "HIV-1 Immunogen", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS Vaccines", 
            "CD4 Lymphocyte Count", 
            "Salk HIV Immunogen"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Carlsbad", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92008"
                }, 
                "name": "Immune Response Corp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002172"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Immune Response Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1995"
    }, 
    "geocoordinates": {
        "Immune Response Corp": "33.158 -117.351"
    }
}